Varubi
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $82,497 | 2 | 0 |
| 2021 | $38,475 | 4 | 0 |
| 2018 | $74,831 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $195,804 | 8 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase II Randomized Study to Evaluate Efficacy, Patient Satisfaction, and Compliance of the Oral Combination of Rolapitant (Varubi) Plus Ondansetron v. Ondansetron Monotherapy in Malignant Glioma Patients Receiving Radiotherapy and Concomitant Temozolomide | TerSera Therapeutics LLC | $120,973 | 0 |
| Effects of Rolapitant on Nausea/vomitting in Patients with Sarcoma Receiving Multi-day Highly Emetogenic Chemotherapy (HEC) with Doxorubicin and Ifosfamide Regimen (AL) | TerSera Therapeutics LLC | $49,655 | 0 |
| Phase II Randomized Study to Evaluate Efficacy, Patient Satisfaction, and Compliance of the Oral Combination of Roliapitant (Varubi(R)) Plus Ondansetron vs. Ondanestron Monotherapy in Mallignant Glioma Patients Receiving Radiotherapy (RT) and Concomitant Temozolmide | TerSera Therapeutics LLC | $25,177 | 0 |
Top Doctors Receiving Payments for Varubi
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Durham, NC | $195,804 | 8 |
Manufacturing Companies
- TerSera Therapeutics LLC $195,804
Product Information
- Type Drug
- Total Payments $195,804
- Total Doctors 0
- Transactions 8
About Varubi
Varubi is a drug associated with $195,804 in payments to 0 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is TerSera Therapeutics LLC.
Payment data is available from 2018 to 2022. In 2022, $82,497 was paid across 2 transactions to 0 doctors.
The most common payment nature for Varubi is "Unspecified" ($195,804, 100.0% of total).
Varubi is associated with 3 research studies, including "Phase II Randomized Study to Evaluate Efficacy, Patient Satisfaction, and Compliance of the Oral Combination of Rolapitant (Varubi) Plus Ondansetron v. Ondansetron Monotherapy in Malignant Glioma Patients Receiving Radiotherapy and Concomitant Temozolomide" ($120,973).